Ontology highlight
ABSTRACT:
SUBMITTER: Abbas HA
PROVIDER: S-EPMC6782026 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Abbas Hussein A HA Alfayez Mansour M Kadia Tapan T Ravandi-Kashani Farhad F Daver Naval N
Cancer management and research 20191004
<i>Fms-related-tyrosine kinase 3</i> (<i>FLT3</i>) mutations occur in approximately a third of acute myeloid leukemia (AML) patients and confer an adverse prognosis. Numerous studies have evaluated <i>FLT3</i> targeting as single agent and in combination approaches in frontline and relapsed AML. At this time, midostaurin, a multikinase inhibitor, is the only FLT3-inhibitor that is US FDA approved to be used in combination with induction therapy in the frontline <i>FLT3-</i>mutated AML setting ba ...[more]